Navigation Links
Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
Date:7/9/2009

SEATTLE, July 9 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal delivery technology, which administers lidocaine and epinephrine through the skin via a mild electric current, has demonstrated safety and efficacy in a Phase 2 clinical trial.

About the Trial:

The trial conducted was a Phase 2, double-blind, randomized, placebo-controlled, two-arm study evaluating the safety and efficacy of the administration of lidocaine and epinephrine using the IDDS to provide topical anesthesia in adults undergoing a venipuncture procedure. Eighty-nine (89) healthy volunteer subjects were treated at two clinical sites. The trial included subjects representing a wide range of ages and ethnicity. Subjects were randomized to receive an 8 minute administration of lidocaine plus epinephrine (Active arm) or epinephrine alone (Placebo arm) at the site of insertion of an intravenous catheter. After placement of the intravenous catheter, subjects evaluated their pain using the Visual Analog pain Scale (VAS) scoring system and were asked if they would use the IDDS again. Safety of the treatment was also monitored during the trial.

Results:

In the Per-Protocol population (including subjects completing 8 minutes of treatment) the mean Visual Analog pain Scale (VAS) results recorded by the subject following the venipuncture procedure were 16.4 mm for the Active treatment versus 24.0 mm for the Placebo treatment (p=0.0235). Therefore, the trial demonstrated statistically lower VAS scores for the Active group as compared to the Placebo group. In addition, more than 80% of the Active group reported pain elimination and willingness to undergo IDDS treatment again. The IDDS treatment was well tolerated, with no serious adverse event reported in any subject.

"This represents a major advancement for Dharma and the Transcu Group," said Paul R. Sleath, President and CEO of Dharma Therapeutics. "We are very excited about this product and the improvements over Dharma's prototype evaluated in earlier clinical trials. Our current design is very user friendly and can be manufactured cost efficiently at commercial scale. We believe our product will be highly attractive to consumers, as it has been designed to meet the market demand for a low cost, fast onset local anesthesia product."

Dharma has an end-of-phase 2 meeting scheduled with the Food and Drug Administration for this fall and plans to embark on pivotal Phase 3 trials in early 2010.


'/>"/>
SOURCE Dharma Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting
2. New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery
3. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
4. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
7. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
8. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
11. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), ... in Lakewood, Colorado . The reputable clinic ... Lipkin , PT, DPT with his staff of four clinicians. ... of Pittsburgh and brings over 10 years of experience with ... Belmar PT marks the 10th PRN clinic in and ...
(Date:8/8/2017)... Aug. 8, 2017   ... diluted (GAAP) loss per share from continuing operations ... revenues increased 16 percent to $110 million ... 27 percent to $161 million ... from continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
Breaking Medicine Technology:
(Date:8/21/2017)... Aliso Viejo, CA (PRWEB) , ... August 21, 2017 , ... ... Pixel Film Studios. Editors can quickly and easily add washed color grades to ... an image. The LUT changes every pixel’s color to the corresponding color indicated by ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... Five chefs ... and awareness for Alzheimer’s Family Center. , Guests will be able to vote ... Beach Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic ...
(Date:8/21/2017)... ... August 21, 2017 , ... Duncan Insurance Agency ... the people of Michigan. The new initiative fundraises for the Kalamazoo Humane Society ... forefront of animal protection and welfare by addressing the root causes of pet ...
(Date:8/21/2017)... ... August 21, 2017 , ... PIXACORE , an independent full-service agency ... Top 100 agencies of the year by MM&M. , This is the first time ... important milestone for the agency. PIXACORE’s newfound recognition reflects its steady trajectory of ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon ... reform plan, has announced his candidacy for the 52nd Congressional District currently held by ... America’s Promise. Coming to this country at age eleven after suffering homelessness and hardship ...
Breaking Medicine News(10 mins):